Ciprofloxacin vs an aminoglycoside in combination with a β-lactam for the treatment of febrile neutropenia: A meta-analysis of randomized controlled trials

Mayo Clinic Proceedings

Volumn 80, Issue 9, 2005, Pages 1146-1156

  Bliziotis, Ioannis A ^a   Michalopoulos, Argyris ^a,b   Kasiakou, Sofia K ^a   Samonis, George ^c   Christodoulou, Christos ^b   Chrysanthopoulou, Stavroula ^a   Falagas, Matthew E ^a,b,d  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c UNIVERSITY OF CRETE   (Greece)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B; AZLOCILLIN; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; NETILMICIN; PENICILLIN G; PENICILLIN V; PIPERACILLIN; TOBRAMYCIN;

ARTICLE; BONE MARROW TRANSPLANTATION; CANCER PATIENT; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEBRILE NEUTROPENIA; HOSPITAL PATIENT; HUMAN; INFECTION; MEDLINE; META ANALYSIS; MORTALITY; NEPHROTOXICITY; OUTCOMES RESEARCH; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCISEARCH; SIDE EFFECT; SYSTEMATIC REVIEW;

EID: 24144457248     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/80.9.1146     Document Type: Article

References (39)

1. Klastersky J. Empirical antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Recent Results Cancer Res. 1988;108:53-60.
2. Rhomberg PR, Jones RN, Sader HS, Fritsche TR, MYSTIC Programme Study Group. Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003). Diagn Microbiol Infect Dis. 2004;49:273-281.
3. Kiffer CR, Mendes C, Kuti JL, Nicolau DP. Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002. Diagn Microbiol Infect Dis. 2004;49:109-116.
4. Cabezudo I, Pfaller MA, Barrett M, Bale M, Wenzel RP. In vitro comparison of mezlocillin and piperacillin plus tobramycin or gentamicin versus 100 gram-negative nosocomial bloodstream isolates. Am J Infect Control. 1990;18:250-256.
5. Jenkins SG. Activity of cefotaxime/desacetylcefotaxime with two aminoglycosides against gram-negative pathogens: an example of interactive synergy. Diagn Microbiol Infect Dis. 1989;12;51-55.
6. Whiting JL, Cheng N, Chow AW. Interactions of ciprofloxacin with clindamycin, metronidazole, cefoxitin, cefotaxime, and mezlocillin against gram-positive and gram-negative anaerobic bacteria. Antimicrob Agents Chemother. 1987;31:1379-1382.
7. Bustamante CI, Wharton RC, Wade JC. In vitro activity of ciprofloxacin in combination with ceftazidime, aztreonam, and azlocillin against multiresistant isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1990;34:1814-1815.
8. Aubert G, Pozzetto B, Dorche G. In vitro effect of new fluoroquinolones and betalactamines combinations against enterococci [in French]. Pathol Biol (Paris). 1991;39:1006-1008.
9. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
10. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
11. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127:820-826.
12. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
13. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
15. Chan CC, Oppenheim BA, Anderson H, Swindell R, Scarffe JH. Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients. Antimicrob Agents Chemother. 1989;33:87-91.
16. Flaherty JP, Waitley D, Edlin B, et al. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. Am J Med. 1989;87(5A):278S-282S.
17. Giamarellou H, Bassaris HP, Petrikkos G, et al. Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrob Agents Chemother. 2000;44:3264-3271.
18. Glauser MP, Brennscheidt U, Cornely O, et al. Clinafloxacin monotherapy (CI-960) versus ceftazidime plus amikacin for empirical treatment of febrile neutropenic cancer patients. Clin Microbiol Infect. 2002;8:14-25.
19. Griggs JJ, Blair EA, Norton JR, Rowe JM, Flesher WR, Betts RF. Ciprofloxacin plus piperacillin is an equally effective regimen for empiric therapy in febrile neutropenic patients compared with standard therapy. Am J Hematol. 1998;58:293-297.
20. Hidalgo M, Hornedo J, Lumbreras C, et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer. 1999;85:213-219.
21. Hyatt DS, Rogers TR, McCarthy DM, Samson DS. A randomized trial of ciprofloxacin plus azlocillin versus netilmicin plus azlocillin for the empirical treatment of fever in neutropenic patients [letter]. J Antimicrob Chemother. 1991;28:324-326.
22. Johnson PR, Liu Yin JA, Tooth JA. A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients. J Antimicrob Chemother. 1992;30:203-214.
23. Kelsey SM, Wood ME, Shaw E, Jenkins GC, Newland AC. A comparative study of intravenous ciprofloxacin and benzylpenicillin versus netilmicin and piperacillin for the empirical treatment of fever in neutropenic patients. J Antimicrob Chemother. 1990;25:149-157.
24. Kelsey SM, Collins PW, Delord C, Weinhard B, Newland AC. A randomized study of teicoplanin plus ciprofloxacin versus gentamicin plus piperacillin for the empirical treatment of fever in neutropenic patients. Br J Haematol 1990;76(suppl 2):10-13.
25. Kern WV, Cometta A, De Bock R, et al, International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med. 1999;341:312-318.
26. Kremery V Jr, Fuchsberger P, Trupl J, et al. Ciprofloxacin plus vancomycin versus ceftazidime plus gentamicin in the treatment of pneumonia in granulocytopenic patients with or without venous catheters: short communication. Chemotherapy. 1992;38:271-274.
27. Madiajagane R, Maitreyan V, Sagar TG, Shanta V. Antibiotics in febrile neutropenia: a randomized prospective comparison of two combinations. Natl Med J India. 1993;6:61-70.
28. Maiche AG, Teerenhovi L. Empiric treatment of serious infections in patients with cancer: randomised comparison of two combinations. Infection. 1991;19(suppl 6):S326-S329.
29. Malik IA, Abbas Z, Karim M. Randomised comparison of oral ofloxacin alone with combination of patenteral antibiotics in neutropenic febrile patients [published correction appears in Lancet. 1992;340:128], Lancet. 1992;339:1092-1096.
30. Meunier F, Zinner SH, Gaya H, et al. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors: The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group. Antimicrob Agents Chemother. 1991;35:873-878.
31. Nenova IS, Goranov SE, Mateva NG, Ananoshtev NH. Treatment with fluorated quinolones of febrile neutropenia in patients with hematologic malignancies. Folia Mea (Plovdiv). 2003;45:13-19.
32. Paganini H, Rodriguez-Brieshcke T, Zubizarreta P, et al. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. Cancer. 2001;91:1563-1567.
33. Paganini H, Gomez S, Ruvinsky S, et al. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina. Cancer. 2003;97:1775-1780.
34. Peacock JE, Herrington DA, Wade JC, et al. Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients: a randomized, double-blind trial. Ann Intern Med. 2002;137:77-87.
35. Philpott-Howard JN, Barker KF, Wade JJ, Kaczmarski RS, Smedley JC, Mufti GJ. Randomized multicentre study of ciprofloxacin and azlocillin versus gentamicin and azlocillin in the treatment of febrile neutropenic patients. J Antimicrob Chemother. 1990;26(suppl F):89-99.
36. Velasco E, Costa MA, Martins CA, Nucci M. Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients. Am J Clin Oncol. 1995;18:429-435.
37. Anaissie EJ, Samonis G, Kalbakis K, Georgoulias V. Therapy for low-risk cancer patients with fever and neutropenia: results of a prospective, randomized trial with cost analysis [abstract]. Abstr Intersci Conf Antimicrob Agents Chemother. 1997;37:373. Abstract LM-51.
38. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-751.
39. Link H, Bohme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol. 2003;82(suppl 2):S105-S117.